Cargando…
Targeting the Hippo Pathway for Breast Cancer Therapy
Breast cancer (BC) is one of the most prominent diseases in the world, and the treatments for BC have many limitations, such as resistance and a lack of reliable biomarkers. Currently the Hippo pathway is emerging as a tumor suppressor pathway with its four core components that regulate downstream t...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266939/ https://www.ncbi.nlm.nih.gov/pubmed/30400599 http://dx.doi.org/10.3390/cancers10110422 |
_version_ | 1783375951649832960 |
---|---|
author | Wu, Liqing Yang, Xiaolong |
author_facet | Wu, Liqing Yang, Xiaolong |
author_sort | Wu, Liqing |
collection | PubMed |
description | Breast cancer (BC) is one of the most prominent diseases in the world, and the treatments for BC have many limitations, such as resistance and a lack of reliable biomarkers. Currently the Hippo pathway is emerging as a tumor suppressor pathway with its four core components that regulate downstream transcriptional targets. In this review, we introduce the present targeted therapies of BC, and then discuss the roles of the Hippo pathway in BC. Finally, we summarize the evidence of the small molecule inhibitors that target the Hippo pathway, and then discuss the possibilities and future direction of the Hippo-targeted drugs for BC therapy. |
format | Online Article Text |
id | pubmed-6266939 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62669392018-12-03 Targeting the Hippo Pathway for Breast Cancer Therapy Wu, Liqing Yang, Xiaolong Cancers (Basel) Review Breast cancer (BC) is one of the most prominent diseases in the world, and the treatments for BC have many limitations, such as resistance and a lack of reliable biomarkers. Currently the Hippo pathway is emerging as a tumor suppressor pathway with its four core components that regulate downstream transcriptional targets. In this review, we introduce the present targeted therapies of BC, and then discuss the roles of the Hippo pathway in BC. Finally, we summarize the evidence of the small molecule inhibitors that target the Hippo pathway, and then discuss the possibilities and future direction of the Hippo-targeted drugs for BC therapy. MDPI 2018-11-05 /pmc/articles/PMC6266939/ /pubmed/30400599 http://dx.doi.org/10.3390/cancers10110422 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wu, Liqing Yang, Xiaolong Targeting the Hippo Pathway for Breast Cancer Therapy |
title | Targeting the Hippo Pathway for Breast Cancer Therapy |
title_full | Targeting the Hippo Pathway for Breast Cancer Therapy |
title_fullStr | Targeting the Hippo Pathway for Breast Cancer Therapy |
title_full_unstemmed | Targeting the Hippo Pathway for Breast Cancer Therapy |
title_short | Targeting the Hippo Pathway for Breast Cancer Therapy |
title_sort | targeting the hippo pathway for breast cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266939/ https://www.ncbi.nlm.nih.gov/pubmed/30400599 http://dx.doi.org/10.3390/cancers10110422 |
work_keys_str_mv | AT wuliqing targetingthehippopathwayforbreastcancertherapy AT yangxiaolong targetingthehippopathwayforbreastcancertherapy |